|
1
|
Hennenberg M, Biecker E, Trebicka J, et
al: Defective RhoA/Rho-kinase signaling contributes to vascular
hypocontractility and vasodilation in cirrhotic rats.
Gastroenterology. 130:838–854. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou Q, Hennenberg M, Trebicka J, et al:
Intrahepatic upregulation of RhoA and Rho-kinase signalling
contributes to increased hepatic vascular resistance in rats with
secondary biliary cirrhosis. Gut. 55:1296–1305. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bari K and Garcia-Tsao G: Treatment of
portal hypertension. World J Gastroenterol. 18:1166–1175. 2012.
View Article : Google Scholar
|
|
4
|
Miñano C and Garcia-Tsao G: Clinical
pharmacology of portal hypertension. Gastroenterol Clin North Am.
39:681–695. 2010.
|
|
5
|
van Beuge MM, Prakash J, Lacombe M, et al:
Reduction of fibrogenesis by selective delivery of a Rho kinase
inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther.
337:628–635. 2011.PubMed/NCBI
|
|
6
|
Ikeda H, Nagashima K, Yanase M, et al:
Involvement of Rho/Rho kinase pathway in regulation of apoptosis in
rat hepatic stellate cells. Am J Physiol Gastrointest Liver
Physiol. 285:G880–G886. 2003.PubMed/NCBI
|
|
7
|
Sohail MA, Hashmi AZ, Hakim W, et al:
Adenosine induces loss of actin stress fibers and inhibits
contraction in hepatic stellate cells via Rho inhibition.
Hepatology. 49:185–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Beuge MM, Prakash J, Lacombe M, Post
E, Reker-Smit C, Beljaars L and Poelstra K: Increased liver uptake
and reduced hepatic stellate cell activation with a cell-specific
conjugate of the Rho-kinase inhibitor Y27632. Pharm Res.
28:2045–2054. 2011.PubMed/NCBI
|
|
9
|
Trebicka J, Hennenberg M, Laleman W, et
al: Atorvastatin lowers portal pressure in cirrhotic rats by
inhibition of RhoA/Rho-kinase and activation of endothelial nitric
oxide synthase. Hepatology. 46:242–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anegawa G, Kawanaka H, Yoshida D, et al:
Defective endothelial nitric oxide synthase signaling is mediated
by rho-kinase activation in rats with secondary biliary cirrhosis.
Hepatology. 47:966–977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brandão DF, Ramalho LN, Ramalho FS,
Zucoloto S, de Martinelli AL and de Silva OC: Liver cirrhosis and
hepatic stellate cells. Acta Cir Bras. 21(Suppl 1): S54–S57.
2006.
|
|
12
|
Chakraborty JB, Oakley F and Walsh MJ:
Mechanisms and biomarkers of apoptosis in liver disease and
fibrosis. Int J Hepatol. 2012:6489152012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cichoz-Lach H, Celinski K, Slomka M and
Kasztelan-Szczerbinska B: Pathophysiology of portal hypertension. J
Physiol Pharmacol. 59(Suppl 2): S231–S238. 2008.
|
|
14
|
Friedman SL: Mechanisms of hepatic
fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Charlton-Menys V and Durrington PN: Human
cholesterol metabolism and therapeutic molecules. Exp Physiol.
93:27–42. 2008. View Article : Google Scholar
|
|
16
|
Lee MH, Cho YS and Han YM: Simvastatin
suppresses self-renewal of mouse embryonic stem cells by inhibiting
RhoA geranylgeranylation. Stem Cells. 25:1654–1663. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmidmaier R, Baumann P, Simsek M,
Dayyani F, Emmerich B and Meinhardt G: The HMG-CoA reductase
inhibitor simvastatin overcomes cell adhesion-mediated drug
resistance in multiple myeloma by geranylgeranylation of Rho
protein and activation of Rho kinase. Blood. 104:1825–1832. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martinez-Sales V, Vila V, Ferrando M and
Reganon E: Atorvastatin neutralises the thrombin-induced tissue
factor expresion in endothelial cells via geranylgeranyl
pyrophosphate. Cytotechnology. 63:1–5. 2011. View Article : Google Scholar
|
|
19
|
Luo W, Meng Y, Ji HL, et al:
Spironolactone lowers portal hypertension by inhibiting liver
fibrosis, ROCK-2 activity and activating NO/PKG pathway in the
bile-duct-ligated rat. PLoS One. 7:e342302012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piao RL, Brigstock DR, Zhu J, Zhang ML and
Gao RP: Clinical significance of connective tissue growth factor in
hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol.
18:2280–2286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Q, Liu X, Chen W and Zhang Z:
Inhibiting adenoid cystic carcinoma cells growth and metastasis by
blocking the expression of ADAM 10 using RNA interference. J Transl
Med. 8:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiroutová A, Majdiaková L, Cermáková M,
Köhlerová R and Kanta J: Expression of cytoskeletal proteins in
hepatic stellate cells isolated from normal and cirrhotic rat
liver. Acta Medica (Hradec Kralove). 48:137–144. 2005.PubMed/NCBI
|
|
23
|
Kim KY, Choi I and Kim SS: Purification
and characterization of a novel inhibitor of the proliferation of
hepatic stellate cells. J Biochem. 127:23–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olaso E, Arteta B, Benedicto A, Crende O
and Friedman SL: Loss of discoidin domain receptor 2 promotes
hepatic fibrosis after chronic carbon tetrachloride through altered
paracrine interactions between hepatic stellate cells and
liver-associated macrophages. Am J Pathol. 179:2894–2904. 2011.
View Article : Google Scholar
|
|
25
|
March S, Graupera M, Rosa Sarrias M,
Lozano F, Pizcueta P, Bosch J and Engel P: Identification and
functional characterization of the hepatic stellate cell CD38 cell
surface molecule. Am J Pathol. 170:176–187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vairetti M, Richelmi P, Bertè F, Currin
RT, Lemasters JJ and Imberti R: Role of pH in protection by low
sodium against hypoxic injury in isolated perfused rat livers. J
Hepatol. 44:894–901. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kukan M, Szatmáry Z, Lutterová M, Kuba D,
Vajdová K and Horecký J: Effects of sizofiran on endotoxin-enhanced
cold ischemia-reperfusion injury of the rat liver. Physiol Res.
53:431–437. 2004.PubMed/NCBI
|
|
28
|
Vairetti M, Ferrigno A, Carlucci F, et al:
Subnormothermic machine perfusion protects steatotic livers against
preservation injury: a potential for donor pool increase? Liver
Transpl. 15:20–29. 2009. View
Article : Google Scholar
|
|
29
|
Kim MY, Baik SK and Lee SS: Hemodynamic
alterations in cirrhosis and portal hypertension. Korean J Hepatol.
16:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reynaert H, Urbain D and Geerts A:
Regulation of sinusoidal perfusion in portal hypertension. Anat Rec
(Hoboken). 291:693–698. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Busafi SA, McNabb-Baltar J, Farag A and
Hilzenrat N: Clinical manifestations of portal hypertension. Int J
Hepatol. 2012:2037942012.PubMed/NCBI
|
|
32
|
Bishop AL and Hall A: Rho GTPases and
their effector proteins. Biochem J. 348:241–255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Zheng XR, Riddick N, Bryden M,
Baur W, Zhang X and Surks HK: ROCK isoform regulation of myosin
phosphatase and contractility in vascular smooth muscle cells. Circ
Res. 104:531–540. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ho JH and Hong CY: Salvianolic acids:
small compounds with multiple mechanisms for cardiovascular
protection. J Biomed Sci. 18:302011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu H, Zhou Y, Lu C, Ping J and Xu LM:
Salvianolic acid B lowers portal pressure in cirrhotic rats and
attenuates contraction of rat hepatic stellate cells by inhibiting
RhoA signaling pathway. Lab Invest. 92:1738–1748. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ardiansyah, Ohsaki Y, Shirakawa H, Koseki
T and Komai M: Novel effects of a single administration of ferulic
acid on the regulation of blood pressure and the hepatic lipid
metabolic profile in stroke-prone spontaneously hypertensive rats.
J Agric Food Chem. 56:2825–2830. 2008. View Article : Google Scholar
|
|
37
|
Huang Z, Wei W and Zhong Q: Effect of
sodium ferulate on hemodynamics in hepatic cirrhosis patients with
portal hypertension. Zhongguo Zhong Xi Yi Jie He Za Zhi.
28:640–642. 2008.(In Chinese).
|
|
38
|
Dudzinski DM and Michel T: Life history of
eNOS: partners and pathways. Cardiovasc Res. 75:247–260. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shiga N, Hirano K, Hirano M, Nishimura J,
Nawata H and Kanaide H: Long-term inhibition of RhoA attenuates
vascular contractility by enhancing endothelial NO production in an
intact rabbit mesenteric artery. Circ Res. 96:1014–1021. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Uehara H, Akahoshi T, Kawanaka H, et al:
Endothelin-1 derived from spleen-activated Rho-kinase pathway in
rats with secondary biliary cirrhosis. Hepatol Res. 42:1039–1047.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Verbeke L, Farre R, Trebicka J, et al:
Obeticholic acid, a farnesoid-X receptor agonist, improves portal
hypertension by two distinct pathways in cirrhotic rats.
Hepatology. Nov 20–2013.(Epub ahead of print). View Article : Google Scholar
|
|
42
|
Meng LQ, Tang JW, Wang Y, et al:
Astragaloside IV synergizes with ferulic acid to inhibit renal
tubulointerstitial fibrosis in rats with obstructive nephropathy.
Br J Pharmacol. 162:1805–1818. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alam MA, Sernia C and Brown L: Ferulic
acid improves cardiovascular and kidney structure and function in
hypertensive rats. J Cardiovasc Pharmacol. 61:240–249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim HY, Park J, Lee KH, Lee DU, Kwak JH,
Kim YS and Lee SM: Ferulic acid protects against carbon
tetrachloride-induced liver injury in mice. Toxicology.
282:104–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rukkumani R, Aruna K, Suresh Varma P and
Padmanabhan Menon V: Hepatoprotective role of ferulic acid: a
dose-dependent study. J Med Food. 7:456–461. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu X, Xiao H, Zhao J and Zhao T:
Cardioprotective effect of sodium ferulate in diabetic rats. Int J
Med Sci. 9:291–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang BH and Ou-Yang JP: Pharmacological
actions of sodium ferulate in cardiovascular system. Cardiovasc
Drug Rev. 23:161–172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lowyck I and Fevery J: Statins in
hepatobiliary diseases: effects, indications and risks. Acta
Gastroenterol Belg. 70:381–388. 2007.PubMed/NCBI
|
|
49
|
Lin Z, Gu J, Xiu J, Mi T, Dong J and
Tiwari JK: Traditional chinese medicine for senile dementia. Evid
Based Complement Alternat Med. 2012:6926212012.PubMed/NCBI
|
|
50
|
Holmberg B, Brännström M, Bucht B,
Crougneau V, Dimeny E, Ekspong A, Granroth B, Gröntoft KC, Hadimeri
H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L,
Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM and
Stegmayr BG: Safety and efficacy of atorvastatin in patients with
severe renal dysfunction. Scand J Urol Nephrol. 39:503–510. 2005.
View Article : Google Scholar : PubMed/NCBI
|
